Johnson & Johnson Discontinues Phase 3 Study Evaluating Respiratory Syncytial Virus Vaccine

The company announced the initiation of the EVERGREEN study, which was aimed to evaluate the efficacy, safety, and immunogenicity of the investigational respiratory syncytial virus vaccine, in 2021.

Related Keywords

United States ,America , ,Advisory Committee ,Pfizer ,Janssen Pharmaceutical Companies Of Johnson ,Products Advisory Committee ,Johnson ,Janssen Pharmaceutical Companies ,Chief External Innovation ,North America ,Related Biological Products Advisory Committee ,